Objective:

To track outcomes, safety, and patient experience over time in patients with relapsing multiple sclerosis starting BRUMVI.

Approach:

Key Findings:

• The study aims to gather real-world evidence on BRUMVI's performance in everyday clinical practice.
• Participants must have a confirmed diagnosis of multiple sclerosis and have not received BRUMVI prior to the study.

Interpretation:

The registry will provide insights into the effectiveness and safety of BRUMVI in a real-world setting, complementing findings from randomized trials.

Limitations:

• Exclusion of patients with recent live vaccinations or active infections.
• Concurrent participation in interventional MS trials is not allowed.

Conclusion:

This registry offers an opportunity for patients starting BRUMVI to contribute to the understanding of its real-world impact while receiving standard care.

Sources:

• Baptist Health Brain & Spine Care
Source

Based on findings from:

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health South Florida, 2026.

https://physicianresources.baptisthealth.net/news/now-enrolling-real-world-registry-study-of-brumvi-ublituximab-xiiy-in-relapsing-multiple-sclerosis

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.